Paydirt
MS
Insider

Mark E Saad

Director

Mark E Saad (Director) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Axsome Therapeutics, Inc. (AXSM). The largest single filing was $6.2M of AXSM (37,577 sh across 2 lots, as filed), executed Dec 31 2025.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells
Median delay
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$6.2M
shares × price, as filed
Last traded
Dec 31 2025
Filed Jan 2

Median ADV $188.5M across their filed names

Open performance
Volume by month
$6.2M$3.1M$0Oct 2024Apr 2025Oct 2025Apr 2026Sep 2025 · sells $1.1MJan 2026 · sells $6.2M
Buys $0 Sells $7.3M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names
AXSM Axsome Therapeutics, Inc. AXSM · 0 buys · 2 sells 2 filings
Recent filings
AXSMSALE Axsome Therapeutics, Inc. View filing → $6.2M
37,577 sh across 2 lots
Exec Dec 31 2025
Filed Jan 2 · 5:30 PM ET
AXSMSALE Axsome Therapeutics, Inc. View filing → $1.1M
9,127 sh × $125.07
Exec Sep 5 2025
Filed Sep 5 2025 · 5:30 PM ET
AXSMSALE Axsome Therapeutics, Inc. View filing → $1.0M
11,016 sh × $91.31
Exec Sep 11 2024
Filed Sep 11 2024 · 5:30 PM ET